US 12419895

Summary of U.S. Patent 12,419,895

A concise summary of U.S. Patent 12,419,895 is provided below, based on the authoritative patent text and public records as of April 30, 2026.

Title: Methods for treating subjects with Prader-Willi syndrome

Assignee: Essentialis Inc.

Inventor: Neil M. Cowen

Filing Date: May 30, 2025

Issue Date: September 23, 2025

Abstract:
The patent describes pharmaceutical formulations of potassium ATP (K-ATP) channel openers and their use, either alone or in combination with growth hormone, for treating various diseases and conditions, including Prader-Willi Syndrome (PWS) and Smith-Magenis syndrome (SMS).

Plain-Language Overview of Independent Claims:

This patent contains several independent claims directed at methods of treating specific symptoms in subjects with Prader-Willi Syndrome (PWS). The core of the invention is the administration of a K-ATP channel opener, a type of drug that affects cellular activity.

• Claim 1: This claim outlines a method for increasing the lean body mass in a person with PWS. It involves administering an effective amount of a K-ATP channel opener for at least four weeks. The treatment can optionally be combined with growth hormone. The claim specifies that the lean body mass should increase by at least 1%.

• Claim 8: This claim focuses on reducing hyperphagia (excessive hunger and food consumption) in a PWS subject. The method involves administering a K-ATP channel opener, optionally with growth hormone, for at least four weeks. The goal is to reduce hyperphagia by at least 10%.

• Claim 12: This claim details a method for reducing body fat in an individual with PWS. It requires administering a K-ATP channel opener, again with the option of adding growth hormone, for a minimum of four weeks to achieve at least a 1% reduction in body fat.

• Claim 16: This claim describes a method for treating a PWS patient who is already receiving growth hormone therapy. The method involves co-administering a K-ATP channel opener to increase their lean body mass.

• Claim 17: Similar to the previous claim, this claim addresses a PWS patient already being treated with a K-ATP channel opener. The method involves adding growth hormone treatment to increase the patient's lean body mass.

There is no information available from the CAFC 2026 dockets regarding this patent. All information is based on the provided patent text.